D-0339-2025 Class II Ongoing

Recalled by Glenmark Pharmaceuticals Inc., USA — Mahwah, NJ

FDA drug recall D-0339-2025 was initiated by Glenmark Pharmaceuticals Inc., USA on Mar 13, 2025 and is designated Class II. Reason for recall: CGMP Deviations The recall status is ongoing.

Recall details

Product Type
Drugs
Report Date
Apr 16, 2025
Initiation Date
Mar 13, 2025
Voluntary/Mandated
Voluntary: Firm initiated

Product description

Rosuvastatin Tablets 40mg, 30-count bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited, Pithampur, Madhya Pradesh 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc. USA, Mahwah, NJ 07430. NDC# 68462-264-30

Reason for recall

CGMP Deviations

Distribution pattern

U.S. Nationwide

Code information

Lot # 17240389, exp. date Feb-26 17240390, exp. date Feb-26 17240426, exp. date Feb-26 17240427, exp. date Feb-26 17240428, exp. date Feb-26 17240778, exp. date Apr-26 17241055, exp. date May-26 17241074, exp. date Jun-26 17241075, exp. date Jun-26 17241091, exp. date Jun-26 17241100, exp. date Jun-26

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0339-2025
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0339-2025. Report a data issue: hello@regdatalab.com.